clinical trial · NCT04354545
Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications
University of California, Los Angeles·—·recruiting·n = 75
GlaucomaOcular Surface DiseaseXiidra (Lifitegrast ophthalmic solution) 5%
brief summary
To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.
started
Apr 1, 2021
primary completion
Dec 1, 2026
completion
Dec 1, 2026
last updated
Mar 13, 2026
detailed description
To assess glaucoma patients' response to treatment with Xiidra (Lifitegrast ophthalmic solution) 5% for ocular surface discomfort caused, in part, by topical glaucoma antihypertensive medications.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol